```
 * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *
```

10/755,166.

```
FILE 'HOME' ENTERED AT 12:35:13 ON 24 MAY 2005

=> file biosis medline caplus wpids usaptfull
'USAPTFULL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'BIOSIS' ENTERED AT 12:35:44 ON 24 MAY 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 12:35:44 ON 24 MAY 2005

FILE 'CAPLUS' ENTERED AT 12:35:44 ON 24 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:35:44 ON 24 MAY 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 12:35:44 ON 24 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s nucleoside? and 5 (2a) termin?
L1        6775 NUCLEOSIDE? AND 5 (2A) TERMIN?

=> s l1 and lipophilic
L2        1809 L1 AND LIPOPHILIC

=> s l2 and 2 (2a) methoxy
L3         799 L2 AND 2 (2A) METHOXY

=> s l3 and plurality
L4         259 L3 AND PLURALITY

=> s l4 and modif? (3a) oligonucleotide?
L5         247 L4 AND MODIF? (3A) OLIGONUCLEOTIDE?

=> s l5 and 5 (4a) lipophilic
L6           5 L5 AND 5 (4A) LIPOPHILIC

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           5 DUP REM L6 (0 DUPLICATES REMOVED)

=> d l7 bib abs 1-5

L7   ANSWER 1 OF 5  USPATFULL on STN
AN     2005:50420  USPATFULL
TI     Derivatized oligonucleotides having improved uptake and other properties
IN     Manoharan, Muthiah, Carlsbad, CA, UNITED STATES
       Cook, Phillip Dan, Carlsbad, CA, UNITED STATES
       Bennett, Clarence Frank, Carlsbad, CA, UNITED STATES
PA     Isis Pharmaceuticals, Inc. (U.S. corporation)
PI     US 2005043219      A1   20050224
AI     US 2004-755166     A1   20040109 (10)
RLI    Continuation of Ser. No. US 2002-73718, filed on 11 Feb 2002, GRANTED,
       Pat. No. US 6831166 Division of Ser. No. US 2000-633659, filed on 7 Aug
```

2000, GRANTED, Pat. No. US 6395492 Division of Ser. No. US 1994-211882, filed on 22 Apr 1994, GRANTED, Pat. No. US 6153737 Continuation-in-part of Ser. No. WO 1992-US9196, filed on 23 Oct 1992, PENDING
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 7
ECL Exemplary Claim: CLM-01-44
DRWN No Drawings
LN.CNT 2116
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Linked **nucleosides** having at least one functionalized **nucleoside** that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic **lipophilic** molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2'-position of the functionalized **nucleoside** via a linking group. If at least a portion of the remaining liked **nucleosides** are 2'-deoxy-2'-fluoro, **2'-O-methoxy**, **2**'-O-ethoxy, 2'-O-propoxy, 2'-O-aminoalkoxy or 2'-O-allyloxy **nucleosides**, the substituent can be attached via a linking group at any of the 3' or the 5' positions of the **nucleoside** or on the heterocyclic base of the **nucleoside** or on the inter-nucleotide linkage linking the **nucleoside** to an adjacent **nucleoside**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 5 USPATFULL on STN
AN 2005:49481 USPATFULL
TI Platelet derived growth factor (PDGF) nucleic acid ligand complexes
IN Janjic, Nebojsa, Boulder, CO, UNITED STATES
Gold, Larry, Boulder, CO, UNITED STATES
PA Gilead Sciences, Inc, Foster City, CA, UNITED STATES, 94404 (U.S. corporation)
PI US 2005042273 A1 20050224
AI US 2003-606159 A1 20030624 (10)
RLI Division of Ser. No. US 2001-851486, filed on 8 May 2001, GRANTED, Pat. No. US 6582918 Division of Ser. No. US 1997-991743, filed on 16 Dec 1997, GRANTED, Pat. No. US 6229002 Continuation-in-part of Ser. No. US 1996-618693, filed on 20 Mar 1996, GRANTED, Pat. No. US 5723594 Continuation-in-part of Ser. No. US 1995-479783, filed on 7 Jun 1995, GRANTED, Pat. No. US 5668264 Continuation-in-part of Ser. No. US 1995-479725, filed on 7 Jun 1995, GRANTED, Pat. No. US 5674685
DT Utility
FS APPLICATION
LREP SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 5 USPATFULL on STN
AN 2005:16419 USPATFULL
TI Methods and compositions for the treatment of MHC-associated conditions
IN Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES
Ling, Song, Ypsilanti, MI, UNITED STATES
PA The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)
PI US 2005013820 A1 20050120
AI US 2004-845407 A1 20040513 (10)
RLI Continuation-in-part of Ser. No. US 2002-161959, filed on 3 Jun 2002, PENDING
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 5430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for counteracting and reversing disease-causing signaling defects in disorders with underlying signal transduction aberrations, including but not limited to rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 5 USPATFULL on STN
AN 2003:51684 USPATFULL
TI Platelet derived growth factor (PDGF) nucleic acid ligand complexes
IN Janjic, Nebojsa, Boulder, CO, UNITED STATES
Gold, Larry, Boulder, CO, UNITED STATES
PI US 2003036642 A1 20030220
US 6582918 B2 20030624
AI US 2001-851486 A1 20010508 (9)
RLI Division of Ser. No. US 1997-991743, filed on 16 Dec 1997, PATENTED Continuation-in-part of Ser. No. US 1996-618693, filed on 20 Mar 1996, PATENTED Continuation-in-part of Ser. No. US 1995-481710, filed on 7 Jun 1995, PATENTED Continuation-in-part of Ser. No. US 1995-479725, filed on 7 Jun 1995, PATENTED
DT Utility
FS APPLICATION
LREP Swanson & Bratschun, L.L.C., Suite 330, 1745 Shea Center Drive, Highlands Ranch, CO, 80129
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 5 USPATFULL on STN
AN 2001:67813 USPATFULL
TI Platelet derived growth factor (PDGF) nucleic acid ligand complexes
IN Janjic, Nebojsa, Boulder, CO, United States

Gold, Larry, Boulder, CO, United States
PA Nexstar Pharmaceuticlas, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6229002 B1 20010508
AI US 1997-991743 19971216 (8)
RLI Continuation-in-part of Ser. No. US 1996-618693, filed on 20 Mar 1996, now patented, Pat. No. US 5723594 Continuation-in-part of Ser. No. US 1995-479783, filed on 7 Jun 1995, now patented, Pat. No. US 5668264 Continuation-in-part of Ser. No. US 1995-479725, filed on 7 Jun 1995, now patented, Pat. No. US 5674685
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie
LREP Swanson & Bratschun LLC
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 3002
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or **Lipophilic** Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

=> d l15 bib abs 1-9

L15 ANSWER 1 OF 9 USPATFULL on STN
AN 2004:247178 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, UNITED STATES
PI US 2004191773 A1 20040930
AI US 2003-371526 A1 20030221 (10)
RLI Continuation of Ser. No. US 2002-78949, filed on 20 Feb 2002, PENDING Continuation of Ser. No. US 2000-479783, filed on 7 Jan 2000, PENDING Division of Ser. No. US 1997-870608, filed on 6 Jun 1997, GRANTED, Pat. No. US 6107094 Continuation-in-part of Ser. No. US 1996-659440, filed on 6 Jun 1996, GRANTED, Pat. No. US 5898031
DT Utility
FS APPLICATION
LREP COZEN O'CONNOR, P.C., 1900 MARKET STREET, PHILADELPHIA, PA, 19103-3508
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 9 USPATFULL on STN
AN 2003:173929 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, UNITED STATES
PI US 2003119777 A1 20030626
AI US 2002-281297 A1 20021025 (10)
RLI Division of Ser. No. US 2000-479783, filed on 7 Jan 2000, PENDING Division of Ser. No. US 1997-870608, filed on 6 Jun 1997, GRANTED, Pat. No. US 6107094 Continuation-in-part of Ser. No. US 1996-659440, filed on 6 Jun 1996, GRANTED, Pat. No. US 5898031
DT Utility
FS APPLICATION
LREP COZEN O'CONNOR, 1900 Market Street, Philadelphia, PA, 19103
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3925
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and

for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 9 USPATFULL on STN
AN 2003:140942 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, UNITED STATES
PI US 2003096784 A1 20030522
AI US 2002-281349 A1 20021025 (10)
RLI Division of Ser. No. US 2000-479783, filed on 7 Jan 2000, PENDING Division of Ser. No. US 1997-870608, filed on 6 Jun 1997, GRANTED, Pat. No. US 6107094 Continuation-in-part of Ser. No. US 1996-659440, filed on 6 Jun 1996, GRANTED, Pat. No. US 5898031
DT Utility
FS APPLICATION
LREP COZEN O'CONNOR, 1900 Market Street, Philadelphia, PA, 19103
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3925
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 9 USPATFULL on STN
AN 2003:140446 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, UNITED STATES
PI US 2003096287 A1 20030522
AI US 2002-281312 A1 20021025 (10)
RLI Division of Ser. No. US 2000-479783, filed on 7 Jan 2000, PENDING Division of Ser. No. US 1997-870608, filed on 6 Jun 1997, GRANTED, Pat. No. US 6107094 Continuation-in-part of Ser. No. US 1996-659440, filed on 6 Jun 1996, GRANTED, Pat. No. US 5898031
DT Utility
FS APPLICATION
LREP COZEN O'CONNOR, 1900 Market Street, Philadelphia, PA, 19103
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 9 USPATFULL on STN
AN 2003:140445 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, UNITED STATES
PI US 2003096286 A1 20030522
AI US 2002-280600 A1 20021025 (10)
RLI Division of Ser. No. US 2000-479783, filed on 7 Jan 2000, PENDING Division of Ser. No. US 1997-870608, filed on 6 Jun 1997, GRANTED, Pat. No. US 6107094 Continuation-in-part of Ser. No. US 1996-659440, filed on 6 Jun 1996, GRANTED, Pat. No. US 5898031
DT Utility
FS APPLICATION
LREP COZEN O'CONNOR, 1900 Market Street, Philadelphia, PA, 19103
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 9 USPATFULL on STN
AN 2002:314673 USPATFULL
TI Derivatized oligonucleotides having improved uptake and other properties
IN Manoharan, Muthiah, Carlsbad, CA, UNITED STATES
Cook, Phillip Dan, Carlsbad, CA, UNITED STATES
Bennett, Clarence Frank, Carlsbad, CA, UNITED STATES
PA ISIS Pharmaceutical, Inc. (U.S. corporation)
PI US 2002177150 A1 20021128
US 6831166 B2 20041214
AI US 2002-73718 A1 20020211 (10)

RLI Division of Ser. No. US 2000-633659, filed on 7 Aug 2000, GRANTED, Pat. No. US 6395492 Division of Ser. No. US 1998-211882, filed on 15 Dec 1998, GRANTED, Pat. No. US 6373826 Continuation-in-part of Ser. No. WO 1992-US9196, filed on 23 Oct 1992, UNKNOWN
DT Utility
FS APPLICATION
LREP Woodcock Washburn LLP, 46th Floor, One Liberty Place, Philadelphia, PA, 19103
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2'-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2'-deoxy-2'-fluoro, 2'-O-methoxy, 2'-O-ethoxy, 2'-O-propoxy, 2'-O-aminoalkoxy or 2'-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3' or the 5' positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 9 USPATFULL on STN
AN 2002:295143 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, UNITED STATES
PI US 2002165189 A1 20021107
AI US 2002-78949 A1 20020220 (10)
RLI Continuation of Ser. No. US 2000-479783, filed on 7 Jan 2000, PENDING
DT Utility
FS APPLICATION
LREP Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA, 19103
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 3922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 9 USPATFULL on STN

AN 2000:109600 USPATFULL
TI Oligoribonucleotides and ribonucleases for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, United States
PA Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6107094 20000822
AI US 1997-870608 19970606 (8)
RLI Continuation-in-part of Ser. No. US 1996-659440, filed on 6 Jun 1996, now patented, Pat. No. US 5898031
DT Utility
FS Granted
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: McGarry, Sean
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 3806
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 9 USPATFULL on STN
AN 1999:50839 USPATFULL
TI Oligoribonucleotides for cleaving RNA
IN Crooke, Stanley T., Carlsbad, CA, United States
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 5898031 19990427
AI US 1996-659440 19960606 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John L.
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 3150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:35:13 ON 24 MAY 2005)

     FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:35:44 ON
     24 MAY 2005
L1          6775 S NUCLEOSIDE? AND 5 (2A) TERMIN?
L2          1809 S L1 AND LIPOPHILIC
L3           799 S L2 AND 2 (2A) METHOXY
L4           259 S L3 AND PLURALITY
L5           247 S L4 AND MODIF? (3A) OLIGONUCLEOTIDE?
L6             5 S L5 AND 5 (4A) LIPOPHILIC
L7             5 DUP REM L6 (0 DUPLICATES REMOVED)
L8             0 S PLURALITY  (5A) NUCLEOSIDE? (10A) 2 (2A) SUBSTIT? (10A) 5(3A)
L9             0 S PLURALITY  (15A) NUCLEOSIDE? (20A) 2 (2A) SUBSTIT? (20A) 5(3A
L10            0 S PLURALITY  (5A) NUCLEOSIDE? (10A) 2 (2A) (FLUORO OR ALK?) (10
L11            0 S PLURALITY  (15A) NUCLEOSIDE? (20A) 2 (4A) (FLUORO OR ALK?) (2
L12            0 S PLURALITY  (15A) NUCLEOSIDE? (20A) 2 (7A) (FLUORO OR ALK?) (2
L13           10 S PLURALITY  (15A) NUCLEOSIDE? (20A) 2 (4A) (FLUORO OR ALK?) AN
L14           10 DUP REM L13 (0 DUPLICATES REMOVED)
L15            9 S L14 NOT L7

=>
```